Monday April 23, 2018
What is the 21st Century Cures Act?
The 21st Century Cures Act (Cures Act), signed on December 13, 2016, is intended to support the fast-track of new developments for medical products and provide patients with new modernizations and developments who need them faster and more proficiently.
Why is the 21st Century Cures Act Important in the Life Sciences Industry?
The law supports the FDA's continued work to integrate the patient’s perspectives into the progress of devices, drugs, and bio products within decisions made by the FDA. The Cures Act improves the ability to streamline clinical trial projects and clinical outcome assessments within the Life Sciences industries, which overall, will quicken the development and assessment of new medical products, including medical devices.
According to the Advanced Medical Technology Association, which represents 300 medical device companies, “the Cures Act builds on FDA’s current programs to allow a quicker path for breakthrough medical technologies for patients with life-threatening or irreversibly debilitating diseases or conditions, and limited alternatives.”
How does this Act impact health data?
The 21st Century Cures Act impacts financial support for health research as well as improving mental healthcare. The Act states that within the next two years one billion dollars will be allocated towards programs to prevent opioid abuse. Furthermore, biomedical research will be improved upon with funding totaling 4.8 billion and new cancer research with funding up to 1.8 billion. The data from this research may be ground breaking for the future of medical advances.
The Arbour Advantage
Arbour Group is a trusted regulatory advisor to over 250 pharmaceutical, medical device and biotechnology companies worldwide. Let us demonstrate how we can prove ourselves as a valuable business partner by delivering effective services that reduce compliance costs.